June 14th 2021
June 9th 2021
Sponsored Content by Adaptive Biotechnologies
June 7th 2021
Sponsored Content by Tempus
April 26th 2021
Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.
March 31st 2021
Sponsored Content by Ipsen
March 30th 2021
Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.
December 16th 2020
Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.
October 20th 2020
As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.